Kimberly-Clark May Sell Assets to Clear $40 Billion Kenvue Deal

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Kimberly-Clark prepares concessions for EU antitrust review of $40 billion Kenvue deal
  • Australia mandated sale of Stayfree and Carefree brands to preserve competition
  • Stock down 21.09% over 12 months despite trading near oversold RSI levels
  • Analyst consensus remains Hold with average price target of $112.43
powered bylight_fuzz_icon
51111324

*this image is generated using AI for illustrative purposes only.

Kimberly-Clark Corp. (NYSE: KMB) is preparing concessions to address European Union antitrust concerns regarding its proposed $40 billion acquisition of Kenvue Inc. (NYSE: KVUE). The company may need to divest assets to secure regulatory approval for the transaction.

The European Commission is expected to formally outline its competition concerns this week, according to Reuters. Kimberly-Clark could offer remedies before the preliminary review ends on Sept. 29. Failure to do so could trigger an in-depth investigation lasting approximately four months.

Regulatory Landscape

Australia has already imposed conditions on the deal. The Australian Competition and Consumer Commission approved the acquisition subject to the sale of Kenvue’s Stayfree and Carefree period-care brands to an approved buyer. This divestiture aims to preserve competition in a market previously dominated by three major suppliers: Kimberly-Clark, Kenvue, and Essity.

Market Performance

Kimberly-Clark shares rose 0.33% to $99.00 in premarket trading, while Kenvue shares gained 0.28% to $17.97. Broader market sentiment also improved, with Nasdaq futures up 0.54% and S&P 500 futures up 0.32%.

Despite the morning gains, Kimberly-Clark stock has fallen 21.09% over the past 12 months. The stock remains in a longer-term downtrend, trading below all four major moving averages.

Metric Value Status
Current Price $99.00 Down 21.09% (12M)
20-Day SMA $106.06 Stock is 6.7% below
50-Day SMA $108.28 Stock is 8.6% below
100-Day SMA $104.43 Stock is 5.2% below
200-Day SMA $103.09 Stock is 4.0% below

The relative strength index stands at 30, placing the stock near oversold territory. Resistance sits near $111.50, while support is around $93, close to the 52-week low of $92.42.

Analyst Outlook

The stock carries a Hold consensus rating with an average price forecast of $112.43. Recent analyst actions include:

  • Piper Sandler maintained an Overweight rating and lowered its price forecast to $118 on Sept. 11.
  • Wells Fargo maintained Equal-Weight and cut its forecast to $105 on Sept. 10.
  • UBS maintained Neutral and raised its forecast to $116 on Aug. 5.

What the Numbers Show

Kimberly-Clark’s Benzinga Edge scorecard reveals a divergence between fundamentals and momentum. The company scores 98.09 for Quality and 84.27 for Growth, yet its Momentum score is just 18.66. This gap highlights how prolonged price weakness has overshadowed strong underlying business metrics.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

Which specific assets or business units might Kimberly-Clark be forced to divest to satisfy the European Commission's antitrust concerns?

How could a potential four-month in-depth investigation by the EU impact the timeline and final valuation of the $40 billion deal?

Will other major regulators, such as the US FTC or UK CMA, impose similar divestiture conditions following Australia's precedent?

like15
dislike

South Africa approves Kimberly-Clark, Kenvue deal with conditions

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights

South Africa's Competition Tribunal has cleared the deal between Kimberly-Clark Corporation and Kenvue with conditions. This regulatory approval allows the transaction to move forward while ensuring compliance with local competition laws.

powered bylight_fuzz_icon
48271485

*this image is generated using AI for illustrative purposes only.

South Africa's Competition Tribunal has approved the proposed transaction between Kimberly-Clark Corporation and Kenvue, subject to certain conditions.

The regulatory body granted clearance for the deal, indicating that the merger can proceed provided the companies adhere to the stipulated requirements.

Regulatory Context

The approval from the Competition Tribunal is a significant step in the regulatory process for the cross-border transaction. The conditions imposed by the tribunal are designed to ensure that the merger does not adversely affect competition within the South African market.

No further financial details or specific terms of the conditions were disclosed in the initial report.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific operational or divestiture conditions did the Competition Tribunal impose to mitigate competition concerns in the South African market?

How might this regulatory approval influence Kimberly-Clark's broader strategy for integrating Kenvue's assets globally?

Will this merger trigger a review or impact pricing strategies for consumer health and hygiene products among competitors in Southern Africa?

like19
dislike

More News on Kimberly Clark